A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia

Mostrar otras versiones (1)

BACKGROUND: Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals, accounting for >1 million cases annually in the United States. A live attenuated HZ vaccine (LAV) is Food and Drug Administration approved for those age 50 years or older, though Advisory Committee on Immunization P...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Christopher F, Aljassem, Annas, Stassinopoulos, Jerry, Pisacreta, Giovanni, Hutton, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602903/
https://www.ncbi.nlm.nih.gov/pubmed/31289726
http://dx.doi.org/10.1093/ofid/ofz219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602903/
https://www.ncbi.nlm.nih.gov/pubmed/31289726
http://dx.doi.org/10.1093/ofid/ofz219

Ejemplares similares